Definition and epidemiology
Gigantism refers to abnormally accelerated linear growth and excessive final height resulting from growth hormone (GH) excess that begins before puberty, while the epiphyseal growth plates are still open. It is the pediatric counterpart of acromegaly; when GH excess begins after growth plate fusion, the result is acromegaly rather than gigantism, though many patients eventually show overlapping features of both if the disease persists into adulthood.
Gigantism is extremely rare, with only a few hundred cases described in the literature. It typically presents in childhood or adolescence, with no strong sex predilection reported in most series, though some cohorts show a slight male predominance. Because of its rarity, it is often diagnosed late, after substantial excess growth has already occurred.
- Nearly all cases are due to a GH-secreting pituitary adenoma (somatotroph adenoma)
- A subset occurs in the context of genetic syndromes, particularly McCune-Albright syndrome, multiple endocrine neoplasia type 1 (MEN1), Carney complex, and X-linked acrogigantism (caused by GPR101 duplication)
- Isolated familial pituitary adenoma syndromes can also present with gigantism
- Gigantism = GH excess before growth plate fusion; acromegaly = GH excess after fusion
- Nearly all cases from GH-secreting pituitary somatotroph adenoma
- Screening test: IGF-1; confirmatory test: OGTT with failure of GH suppression
- MRI pituitary with contrast is imaging of choice
- Associated syndromes: McCune-Albright, MEN1, Carney complex, X-LAG (GPR101)
- First-line treatment: transsphenoidal surgical resection
- Pegvisomant = GH receptor antagonist used in medical therapy
- Bitemporal hemianopia suggests macroadenoma compressing optic chiasm
Etiology and risk factors
The overwhelming majority of gigantism cases arise from a benign pituitary somatotroph adenoma that autonomously secretes GH. Hypothalamic tumors secreting growth hormone-releasing hormone (GHRH) are a rarer cause, as is ectopic GHRH or GH secretion from neuroendocrine tumors.
Genetic associations
- McCune-Albright syndrome: GNAS gene mutation causing activating Gs-alpha signaling, associated with cafe-au-lait skin macules, polyostotic fibrous dysplasia, and precocious puberty
- MEN1: mutations in the MEN1 tumor suppressor gene, associated with parathyroid, pancreatic, and pituitary tumors
- Carney complex: PRKAR1A mutations, associated with cardiac myxomas and skin pigmentation abnormalities
- X-linked acrogigantism (X-LAG): microduplication involving GPR101, typically presents in infancy with very rapid growth
- AIP gene mutations: associated with familial isolated pituitary adenomas, often more aggressive and resistant to treatment
Risk factors are largely genetic and syndromic rather than lifestyle-related, reflecting the rarity and tumor-driven nature of the disease.
Pathophysiology
Excess GH acts both directly on tissues and indirectly through stimulation of hepatic insulin-like growth factor 1 (IGF-1) production. Because the epiphyseal growth plates have not yet fused in children, the combined action of GH and IGF-1 on chondrocytes at the growth plate drives excessive longitudinal bone growth, producing abnormally tall stature.
GH also has direct metabolic and tissue effects independent of growth plate status:
- Promotes protein synthesis and lipolysis
- Antagonizes insulin action, predisposing to insulin resistance and glucose intolerance
- Stimulates soft tissue, cartilage, and visceral organ growth (organomegaly)
- Causes periosteal bone growth and soft tissue thickening, producing coarsened facial features even in children
If the adenoma persists or is not controlled through puberty and growth plate fusion, the patient transitions into a clinical picture resembling acromegaly, with continued soft tissue and acral growth despite cessation of linear growth.
Clinical features
The hallmark feature is excessive linear growth leading to tall stature disproportionate for age, family height pattern, and growth curve trajectory. Growth velocity is typically well above the normal percentile for age.
Common findings
- Rapidly increasing height, often crossing growth percentiles upward
- Large hands and feet, increased shoe and glove size
- Coarsening facial features: frontal bossing, prominent jaw (prognathism), thickened lips
- Delayed puberty or, in McCune-Albright syndrome, precocious puberty
- Headaches and visual field defects (bitemporal hemianopia) from mass effect of a macroadenoma on the optic chiasm
- Excessive sweating (hyperhidrosis) and oily skin
- Joint pain and early degenerative arthropathy
- Macroglossia and widened dental spacing
- Fatigue, weakness, and symptoms of glucose intolerance or diabetes in some patients
Parents or clinicians often first notice the child is unusually tall for family stature or is growing faster than peers at well-child visits.
Diagnosis
Diagnosis combines clinical suspicion from growth pattern with biochemical confirmation of GH/IGF-1 excess and pituitary imaging.
Biochemical testing
- Serum IGF-1: elevated for age and sex; a good screening test since IGF-1 reflects integrated GH secretion
- Oral glucose tolerance test (OGTT) with GH measurement: the confirmatory test; in normal physiology, glucose suppresses GH, but in GH-secreting tumors, GH fails to suppress below the normal threshold
- Random GH levels are not reliable alone because of pulsatile secretion
Imaging
- Pituitary MRI with contrast is the imaging study of choice to identify a pituitary adenoma, assess size (microadenoma versus macroadenoma), and evaluate proximity to the optic chiasm and cavernous sinuses
- If no pituitary lesion is found, evaluate for ectopic GHRH or GH secretion with abdominal/chest imaging
Additional workup
- Formal visual field testing if a macroadenoma is present
- Assessment of other pituitary hormone axes (thyroid, adrenal, gonadal) for hypopituitarism from mass effect
- Genetic testing (GNAS, MEN1, AIP, GPR101) when a syndromic cause is suspected, particularly in young children or familial clustering
- Bone age radiographs may show advanced bone age in some cases
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Constitutional tall stature (familial) | Normal GH/IGF-1, tall parents, normal growth velocity pattern |
| Marfan syndrome | Tall with arachnodactyly, lens dislocation, aortic root dilation, normal IGF-1 |
| Klinefelter syndrome | Tall stature with hypogonadism, small testes, karyotype 47,XXY |
| Homocystinuria | Marfanoid habitus with developmental delay, thromboembolism |
| Precocious puberty (other causes) | Early growth spurt but eventual early plate fusion, shorter final height |
| Sotos syndrome | Overgrowth with macrocephaly, learning disability, distinctive facies, normal GH axis |
| Acromegaly | GH excess after growth plate fusion, no increase in height, soft tissue/acral changes only |
Management
Management goals are to normalize GH and IGF-1 levels, control or remove the tumor, prevent further excessive growth, and address complications.
First-line: surgery
- Transsphenoidal surgical resection of the pituitary adenoma is first-line therapy for most patients, particularly those with a discrete adenoma amenable to resection
- Surgery offers the chance of biochemical cure, especially with microadenomas
Medical therapy
Used when surgery is not curative, not feasible, or while awaiting surgery:
- Somatostatin receptor ligands (octreotide, lanreotide) suppress GH secretion
- Pegvisomant, a GH receptor antagonist, lowers IGF-1 and is used when somatostatin analogs are insufficient
- Dopamine agonists (cabergoline) are modestly effective, more so with co-secretion of prolactin
Radiotherapy
- Reserved for residual or recurrent tumor not controlled by surgery or medical therapy, given concerns about hypopituitarism and, in children, effects on surrounding neural structures
Supportive care
- Multidisciplinary endocrinology, neurosurgery, and ophthalmology follow-up
- Monitoring and treatment of hypopituitarism, glucose intolerance, and cardiovascular risk
- Psychosocial support, as extreme height and altered appearance can affect a child's social and emotional development
Guideline consensus from major endocrine societies supports surgery as first-line in nearly all operable cases, with medical therapy as adjunct or alternative; approaches are broadly similar between US (Endocrine Society) and European guidance.
Complications and prognosis
Untreated or poorly controlled gigantism carries significant long-term morbidity and can shorten life expectancy, largely from cardiovascular, metabolic, and mass-effect complications.
Complications
- Cardiomyopathy, hypertension, and increased cardiovascular mortality
- Type 2 diabetes mellitus or impaired glucose tolerance
- Degenerative osteoarthropathy and joint pain from excessive bone/cartilage growth
- Obstructive sleep apnea from soft tissue overgrowth of the airway
- Visual field deficits and headache from macroadenoma mass effect
- Hypopituitarism from tumor compression of normal pituitary tissue
- Psychosocial difficulties related to extreme stature and appearance
Prognosis
Early diagnosis and treatment substantially improve outcomes. Biochemical control after surgery (with or without adjunct medical therapy) can normalize IGF-1 and halt further excessive growth, though height already achieved cannot be reversed. Lifelong follow-up is required to monitor for tumor recurrence and metabolic/cardiovascular complications.
GIANT: GH excess, Immature (open) growth plates, Adenoma (pituitary) usual cause, Needs IGF-1/OGTT testing, Transsphenoidal surgery first-line
Practice questions
1. A 12-year-old boy is brought to clinic because he has grown 15 cm in the past year and is now taller than his father. Examination reveals enlarged hands and feet, frontal bossing, and mild prognathism. Growth plates are open on radiograph. Which test is most appropriate as an initial screening study?
2. A 10-year-old girl with cafe-au-lait macules and a history of a fibrous dysplasia lesion in her femur is found to have excessive linear growth and elevated IGF-1. Genetic testing is most likely to reveal a mutation in which gene?
3. A 14-year-old boy with confirmed GH-secreting pituitary macroadenoma undergoes transsphenoidal surgery but has persistently elevated IGF-1 postoperatively. He has no visual field defects and MRI shows a small residual tumor remnant in the cavernous sinus. Which medical therapy most directly antagonizes the growth hormone receptor itself?
Frequently asked questions
What causes gigantism?
Gigantism is caused almost always by a growth hormone-secreting pituitary adenoma occurring in a child or adolescent whose growth plates are still open. Rarer causes include hypothalamic GHRH-secreting tumors, ectopic GH/GHRH secretion, and genetic syndromes such as McCune-Albright syndrome, MEN1, Carney complex, and X-linked acrogigantism from GPR101 duplication.
What are the first symptoms of gigantism?
The earliest sign is usually unusually rapid linear growth, with the child crossing height percentiles faster than peers and family pattern would predict. Large hands and feet, coarsening facial features, headaches, and excessive sweating often follow as the growth hormone excess continues.
How is gigantism diagnosed?
Diagnosis starts with a screening serum IGF-1 level, which is elevated in GH excess, followed by a confirmatory oral glucose tolerance test showing failure of growth hormone to suppress normally. Pituitary MRI with contrast is then used to locate and characterize the causative adenoma.
Is gigantism curable?
Gigantism is often curable, especially when caused by a small, surgically accessible pituitary adenoma that can be fully removed via transsphenoidal surgery. When surgery alone does not achieve full biochemical control, medical therapy or radiotherapy can normalize hormone levels, though height already gained before treatment cannot be reversed.
Gigantism vs acromegaly — what is the difference?
Both result from growth hormone excess from a pituitary adenoma, but the timing relative to growth plate closure differs. Gigantism occurs in children or adolescents before the epiphyseal plates fuse, causing excessive height, while acromegaly occurs in adults after plate fusion, causing soft tissue and acral enlargement without increased height.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: E22.0
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.